Head and Neck Cancer

Head and neck cancers include cancers of the mouth, nose, sinuses, salivary glands, throat, and lymph nodes in the neck.

Programs + Services


Head + Neck Cancer Center

Visit the Head and Neck Cancer Center to find out more about treatment for all head and neck cancers, including mouth (oral) and throat cancer.
More information about programs and services

Doctors + Care Team

Kathryn Y. Noonan, MD

Kathryn Y. Noonan, MD

Loading ...

Accepting New Patients

Title(s): Neurotologist; Associate Program Director, Otolaryngology Residency Program; Assistant Professor, Tufts University School of Medicine; Clerkship Director, Tufts University School of Medicine
Department(s): Otolaryngology, Neurotology
Appt. Phone: 617-636-8724
Fax #: 617-636-1479

Acoustic neuromas, glomus tumors, and other skull base diseases, cochlear implants and hearing loss disorders, otosclerosis, cholesteatoma, and chronic ear diseases

View Full Profile for Kathryn Y. Noonan, MD

Miriam O'Leary, MD, FACS

Miriam O'Leary, MD, FACS

Loading ...

Accepting New Patients

Virtual Appointments Available

Title(s): Chair, Department of Otolaryngology, Tufts Medical Center; Otolaryngologist; Chair and Associate Professor, Department of Otolaryngology, Tufts University School of Medicine
Department(s): Otolaryngology
Appt. Phone: 617-636-3030
Fax #: 617-636-1479

Head and neck cancer, management of thyroid cancer and hyperparathyroidism, head and neck reconstruction including microvascular techniques, management of radiation-related complications

View Full Profile for Miriam O'Leary, MD, FACS

Daniel Oreadi, DMD

Daniel Oreadi, DMD

Accepting New Patients

Title(s): Oral and Maxillofacial Surgeon; Assistant Professor, Tufts University School of Dental Medicine
Department(s): Dentistry
Appt. Phone: 617-636-6515
Fax #:

Treatment of benign and malignant tumors of the oral cavity, oral cancer, salivary gland tumors, temporomandibular joint surgery, reconstructive surgery of the face and jaws, head and neck trauma, nerve repair, treatment of facial infections, management of head and neck cancer treatment-related complications

View Full Profile for Daniel Oreadi, DMD

Jeremiah C.  Tracy, MD

Jeremiah C. Tracy, MD

Accepting New Patients

Title(s): Otolaryngologist; Head and Neck Surgeon; Associate Professor of Otolaryngology-Head & Neck Surgery, Tufts University School of Medicine
Department(s): Otolaryngology, Head & Neck Surgery
Appt. Phone: 617-636-8711
Fax #: 617-636-1479

Head and neck oncologic surgery, including transoral robotic surgery, microvascular reconstructive surgery and skull base surgery

View Full Profile for Jeremiah C. Tracy, MD

Richard O. Wein, MD, FACS

Richard O. Wein, MD, FACS

Loading ...

Accepting New Patients

Virtual Appointments Available

Title(s): Chief, Division of Head and Neck Surgery; Associate Professor, Tufts University School of Medicine
Department(s): Otolaryngology
Appt. Phone: 617-636-8711
Fax #: 617-636-1479

Head and neck surgical oncology, head and neck reconstruction, management of salivary and thyroid disorders, management of radiation-related complications, maxillofacial trauma, sleep apnea and sleep endoscopy

View Full Profile for Richard O. Wein, MD, FACS

Research + Clinical Trials


EA3191 - A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

This trial will help to determine if either the experimental arm (adjuvant reirradiation plus pembrolizumab, followed by pembrolizumab to complete 12 months total of pembrolizumab and/or pembrolizumab alone for 12 months) significantly improves Overall Survival (OS) compared to adjuvant reirradiation plus concurrent platinum chemotherapy in high risk patients.
More information about research and clinical trials


S2101-Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers – an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that has spread to other places in the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors. A biomarker is a biological molecule found in the blood, other body fluids, or in tissues that is a sign of a normal or abnormal process or a sign of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. The two biomarkers that this trial is studying are "tumor mutational burden" and "tumor inflammation signature." Another purpose of this trial is to help doctors learn if cabozantinib and nivolumab shrink or stabilize the cancer, and whether patients respond differently to the combination depending on the status of the biomarkers.
More information about research and clinical trials